首页> 外文OA文献 >The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

【2h】

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

机译：MUK 8方案：环磷酰胺和地塞米松的随机期II试验与Ixazomib，复发或难治性多发性骨髓瘤（RRMM）患者与亚马亚度胺，Lenalidomide和蛋白酶体抑制剂进行处理后复发

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Samantha Hinsley; Katrina Walker; Debbie Sherratt; Lucy Bailey; Sadie Reed; Louise Flanagan; Sophie McKee; Fiona Brudenell Straw; Bryony Dawkins; David Meads; Holger W. Auner; Martin F. Kaiser; Mark Cook; Sarah Brown; Gordon Cook;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma [J] . Sarah Brown, Samantha Hinsley, Mónica Ballesteros, BMC Hematology . 2016,第1期

机译：MUK五个方案：卡非佐米，环磷酰胺和地塞米松（CCD）与环磷酰胺，硼替佐米（Velcade）和地塞米松（CVD）的II期随机，对照，平行组多中心试验，用于首次复发和原发性难治性多发性骨髓瘤
2. Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies [J] . Fu Weijun, Lu Jin, Jin Jie, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：口腔Ixazomib的整体存活（OS）益处与Lenalalomide和Dexamethasone（IRD）与亚洲患者（PTS）组合的亚洲患者（PTS）的益处（PTS）组合，具有复发和/或难治性多骨髓瘤（RRMM）：汇总 - 从陀螺俱乐部分析 - MM1和中国延续研究
3. Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM) [J] . Dhakal Binod, DSouza Anita, Hamadani Mehdi, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：患者（PTS）中培根蛋白，Ixazomib和地塞米松（BID）的I / II试验试验，复发/难治性多发性骨髓瘤（RRMM）
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. The MUK five protocol: a phase II randomised controlled parallel group multi-centre trial of carfilzomib cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma [O] . Sarah Brown, Samantha Hinsley, Mónica Ballesteros, 2016

机译：MUK五种方案：卡非佐米环磷酰胺和地塞米松（CCD）与环磷酰胺硼替佐米（Velcade）和地塞米松（CVD）的II期随机对照平行组多中心试验用于首次复发和原发性难治性多发性骨髓瘤
7. The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma [O] . 2016

机译：MUK五个方案：卡非佐米，环磷酰胺和地塞米松（CCD）与环磷酰胺，硼替佐米（Velcade）和地塞米松（CVD）的II期随机，对照，平行组，多中心试验，用于首次复发和原发性难治性多发性骨髓瘤

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

著录项

相似文献

相关主题

期刊订阅